TY - JOUR
T1 - Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides
AU - Da Fonseca, Dora P.A.J.
AU - Joosten, Dianne
AU - Van Der Zee, Ruurd
AU - Jue, Danny L.
AU - Singh, Mahavir
AU - Vordermeier, Hans M.
AU - Snippe, Harm
AU - Verheul, André F.M.
PY - 1998/7/1
Y1 - 1998/7/1
N2 - Induction of cytotoxic T lymphocytes (CTLs) by vaccination has been shown to protect against bacterial, viral, and tumoral challenge. The aim of this study was to identify CTL epitopes on the 38-kDa lipoglycoprotein from Mycobacterium tuberculosis. The identification of these CTL epitopes was based on synthesizing peptides designed from the 38-kDa lipoglycoprotein, with known major histocompatibility complex class I (MHC-I) binding motifs (H-2Db), and studying their ability to up-regulate and stabilize MHC-I molecules on the mouse lymphoma cell line RMA-S. To improve the capacity of the identified peptides to induce CTL responses in mice, palmitic acid with a cysteine-serine-serine spacer amino acid sequence was attached to the amino terminus of the peptide. Two of five peptides with H-2Db binding motifs and their corresponding lipopeptides up-regulated and stabilized the H-2Db molecules on RMA-S cells. Both lipopeptides, in combination with incomplete Freund's adjuvant, induced CTL responses in C57BL/6 (H-2(b)) mice. Moreover, the lipopeptide induced stronger CTL responses than the peptide. The capacity of the various lipopeptides to induce CTL displayed a good relationship with the ability of the (lipo)peptide to up-regulate and to stabilize H-2Db molecules. The capacity of the peptides and lipopeptides to up-regulate and stabilize MHC-I expression can therefore be used to predict their potential to function as a CTL epitope. The newly identified CTL epitopes and their lipid derivatives provide us with important information for future M. tuberculosis vaccine design.
AB - Induction of cytotoxic T lymphocytes (CTLs) by vaccination has been shown to protect against bacterial, viral, and tumoral challenge. The aim of this study was to identify CTL epitopes on the 38-kDa lipoglycoprotein from Mycobacterium tuberculosis. The identification of these CTL epitopes was based on synthesizing peptides designed from the 38-kDa lipoglycoprotein, with known major histocompatibility complex class I (MHC-I) binding motifs (H-2Db), and studying their ability to up-regulate and stabilize MHC-I molecules on the mouse lymphoma cell line RMA-S. To improve the capacity of the identified peptides to induce CTL responses in mice, palmitic acid with a cysteine-serine-serine spacer amino acid sequence was attached to the amino terminus of the peptide. Two of five peptides with H-2Db binding motifs and their corresponding lipopeptides up-regulated and stabilized the H-2Db molecules on RMA-S cells. Both lipopeptides, in combination with incomplete Freund's adjuvant, induced CTL responses in C57BL/6 (H-2(b)) mice. Moreover, the lipopeptide induced stronger CTL responses than the peptide. The capacity of the various lipopeptides to induce CTL displayed a good relationship with the ability of the (lipo)peptide to up-regulate and to stabilize H-2Db molecules. The capacity of the peptides and lipopeptides to up-regulate and stabilize MHC-I expression can therefore be used to predict their potential to function as a CTL epitope. The newly identified CTL epitopes and their lipid derivatives provide us with important information for future M. tuberculosis vaccine design.
KW - Animals
KW - Epitopes, T-Lymphocyte
KW - Female
KW - Glycoproteins/immunology
KW - H-2 Antigens/biosynthesis
KW - Histocompatibility Antigen H-2D
KW - Lipoproteins/immunology
KW - Mice
KW - Mice, Inbred C57BL
KW - Molecular Weight
KW - Mycobacterium tuberculosis/immunology
KW - T-Lymphocytes, Cytotoxic/immunology
KW - Tumor Cells, Cultured
UR - http://www.scopus.com/inward/record.url?scp=0031867796&partnerID=8YFLogxK
U2 - 10.1128/iai.66.7.3190-3197.1998
DO - 10.1128/iai.66.7.3190-3197.1998
M3 - Article
C2 - 9632585
AN - SCOPUS:0031867796
SN - 0019-9567
VL - 66
SP - 3190
EP - 3197
JO - Infection and Immunity
JF - Infection and Immunity
IS - 7
ER -